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Degradation of D-2-
hydroxyglutarate in the presence 
of isocitrate dehydrogenase 
mutations
Raffaela S. Berger  1, Lisa ellmann1, Joerg Reinders1,2, Marina Kreutz3, thomas stempfl4, 
Peter J. oefner1 & Katja Dettmer  1
D-2-Hydroxyglutarate (D-2-HG) is regarded as an oncometabolite. It is found at elevated levels 
in certain malignancies such as acute myeloid leukaemia and glioma. It is produced by a mutated 
isocitrate dehydrogenase IDH1/2, a low-affinity/high-capacity enzyme. Its degradation, in contrast, is 
catalysed by the high-affinity/low-capacity enzyme D-2-hydroxyglutarate dehydrogenase (D2HDH). So 
far, it has not been proven experimentally that the accumulation of D-2-HG in IDH mutant cells is the 
result of its insufficient degradation by D2HDH. Therefore, we developed an LC-MS/MS-based enzyme 
activity assay that measures the temporal drop in substrate and compared this to the expression of 
D2HDH protein as measured by Western blot. Our data clearly indicate, that the maximum D-2-HG 
degradation rate by D2HDH is reached in vivo, as vmax is low in comparison to production of D-2-HG 
by mutant IDH1/2. The latter seems to be limited only by substrate availability. Further, incubation of 
IDH wild type cells for up to 48 hours with 5 mM D-2-HG did not result in a significant increase in either 
D2HDH protein abundance or enzyme activity.
Among the oncogenic mutations reported to alter cancer cell metabolism, mutations in isocitrate dehydroge-
nase (IDH), which normally catalyses the oxidative decarboxylation of isocitrate to α-ketoglutarate (αKG), 
have attracted particular attention1,2. Missense mutations in both cytosolic IDH1 and mitochondrial IDH2 are 
identified frequently in grade II and III astrocytomas and oligodendrogliomas, secondary glioblastomas, and 
acute myeloid leukaemia (AML)3,4. The mutations result in a neo-enzymatic activity, i.e. the production of 
D-2-hydroxyglutarate (D-2-HG), but not L-2-HG5,6, from αKG, accompanied by an accumulation of the prod-
uct5. Increased D-2-HG levels, which can be as high as 35 mM in glioma tissue5, are associated with promotion of 
oncogenesis and inhibition of differentiation. Due to its structural similarity to αKG, D-2-HG has been shown to 
exert inhibitory effects on α-ketoglutarate-dependent enzymes7–9, which depicts one possible way of mediating 
metabolic transformation. Additionally, Sulkowski et al. (2017) reported, that elevated concentrations of 2-HG 
cause a homologous recombination (HR) defect10.
D-2-HG is also produced physiologically in low amounts as a by-product of hydroxyl acid-oxoacid-transhydrogenase 
(HOT)-enzyme activity11. There is no specific physiological role of D-2-HG known, but it is sufficiently oxidized back 
to αKG by a specific dehydrogenase located in the mitochondrion. There exists one enzyme for the degradation of each 
enantiomer, D-/L-2-hydroxyglutarate dehydrogenase (D-/L-2HDH)12,13. Deficiencies of D2HDH or L2HDH due to 
germline or post-zygotic mutations result in 2-HG aciduria (2-HGA type I), which is associated with encephalopa-
thy14–16. Reduced expression of L2HDH has been also observed in renal cancer17, but it causes only an about 10-fold 
increase in tumour levels of L-2-HG. In contrast, mutations in IDH1/2 increase D-2-HG levels by two to three orders 
of magnitude. Therefore, it is hypothesized that D-2-HG production by mutated IDH1/2 exceeds the degradation 
capacity of functional D2HDH18,19. This situation is similar to D-2-HGA type II, where a germline mutation in IDH2 
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is present. In these patients, similar to cancer, IDH2 mutation leads to the production and accumulation of D-2-HG in 
the presence of functional D2HDH, which results in an even higher urinary excretion of D-2-HG compared to patients 
with D-2-HGA type I20. This also suggests that D-2-HG production exceeds its degradation and excretion.
We have implemented an HPLC-MS/MS-based assay to measure D-2-HG production and degradation in 
cells to investigate, for the first time, D-2-HG degradation under elevated D-2-HG levels as a result of mutations 
in IDH1/2. We compare the D-2-HG degradation capacities of several cell lines under various conditions. For 
cells producing D-2-HG, we hypothesized that the degradation rate of D-2-HG is increased to meet the elevated 
D-2-HG levels. Such enzyme regulation can be achieved at several levels and, therefore, we measured in addition 
to the enzyme activity of D2HDH also its abundance by Western blot. The results contribute to a better under-
standing of the mechanism of D-2-HG accumulation in tumours with IDH1/2 mutations.
Methods
Cell culture and lysis. The human breast cancer and fibrosarcoma cell lines MCF7 (ATCC HTB-22, 
ATCC, Manassas, Virginia) and HT1080 (ATCC CCL-121) were cultured in DMEM (PAN, Aidenbach, 
Germany) supplemented with 10% fetal calf serum (Biochrom AG, Berlin, Germany), 1% penicillin-strepto-
mycin (PAA Laboratories Inc., Pasching, Austria), and 2 mM L-glutamine (PAA). The human acute lympho-
blastic leukemia cell line CCRF-CEM-C7H2 (kindly provided by R. Kofler, Innsbruck, Austria) and various 
clones of the human colon cancer cell line HCT116 (HD 104-013, HD 104-019, HD 104-020, Horizon Discovery, 
Waterbeach, UK) were cultured in RPMI1640 (PAN) supplemented with 10% fetal calf serum (Biochrom AG) 
and 2 mM L-glutamine (PAN). Adherent cells were sub-cultured by trypsinization followed by centrifugation for 
pelleting, while suspension cells were collected simply by centrifugation (5 min, 200 × g).
D-2-HG dehydrogenase assay. Cell pellets were washed twice with phosphate buffered saline (PBS; 
PAN) and resuspended in assay buffer (20 mM HEPES, 25 mM KCl, 0.05 mM ZnCl2, protease inhibitor cocktail 
(cOmplete EDTA-free, Roche, Basel, Switzerland). Sonication (3 × 10 sec at 90%, Bandelin Sonopuls, HD2070, 
Bandelin electronic GmbH&Co. KG, Berlin, Germany) was performed on ice. Centrifugation at 10,000 × g at 
4 °C for 5 min removed cellular debris. The cell lysate supernatant was used for the dehydrogenase assay and kept 
on ice for a maximum of 6 h until the assay was started by the addition of PMS (Sigma Aldrich, Taufkirchen, 
Germany) and D-2-HG (Sigma Aldrich). PMS was added after an aliquot of the cell lysate had been taken for 
protein quantification. For assaying dehydrogenase activity, the cell lysate supernatant (200–400 µL, larger vol-
umes for more time points) was incubated with increasing concentrations of D-2-HG at 37 °C and gentle shak-
ing (400 rpm). Aliquots of 20 µL were taken over a time period of up to 5 h, stable isotope-labelled standard 
(2,3,3-d3-2-HG, C/D/N Isotopes Inc., Pointe-Claire, Canada; 100 μM in water) was added, before samples were 
immediately quenched in 100 µL of cold methanol to stop the reaction. After extraction, samples were analysed 
by LC-MS/MS (see below). For calculation of rate and Km values, only data points within a linear range of deg-
radation were taken into account. Replicates (n = 3) of cells from two different passages were lysed and used for 
assay experiments.
D-2-HG formation assay. D-2-HG formation was measured using a protocol adapted from Pusch et al.21. 
Briefly, cells were prepared as described for the D2HDH assay and lysed by sonication (3 × 10 sec at 90%, Bandelin 
Sonopuls, HD2070) in assay buffer (50 mM Tris-HCl, pH 7.4, 10 mM NaCl, 2 mM MgCl2, protease inhibitor cocktail 
(Roche)). The assay was started by the addition of different concentrations (100 µM, 1 mM, 5 mM, 10 mM) of αKG 
and 10 mM NADPH. Collection and extraction of aliquots were performed as described for the D2HDH assay.
Sample preparation for 2-HG quantification. For determination of intracellular 2-HG levels, adherent 
cells were washed twice with PBS before 10 µL of stable isotope-labelled internal standard solution (2,3,3-d3-
2-HG, C/D/N Isotopes Inc., Pointe-Claire, Canada; 100 μM in water) were added to cells, which were then 
scraped in 600 µL of 80% cold methanol. Suspension cells were also washed twice with PBS followed by addition 
of internal standard as before and precipitation in 600 µL of 80% cold methanol. For complete extraction, the 
sample was centrifuged at 95,600 × g, (4 °C, 5 min) and the supernatant was collected. The pellet was washed 
twice with 100 µL of 80% methanol and supernatants were combined in a glass vial. Samples were dried using an 
infrared vortex vacuum evaporator (CombiDancer, Hettich AG, Baech, Switzerland) and reconstituted in 50 µL 
of deionised water. The same sample preparation steps were applied to assay aliquots. Metabolite concentrations 
were normalized to protein content.
2-HG quantification by HPLC-MS/MS. HPLC-MS/MS analysis was performed (as described recently)22 
using an Agilent (Boeblingen, Germany) 1200 Series HPLC system coupled to an API 4000 QTRAP (AB 
SCIEX, Darmstadt, Germany) mass spectrometer operating in negative ionization mode. A Discovery HS 
F5-3 HPLC column (15 cm × 2.1 mm, 3 µm; Supelco, Bellefonte, PA, USA) equipped with a Security Guard col-
umn (C18, Phenomenex, Aschaffenburg, Germany) was used. Gradient elution was performed as described in 
Supplementary Table S5 with phase A consisting of 0.1% formic acid (FA) in water (v/v) and 100% acetonitrile 
(ACN) as mobile phase B. The column was kept at 30 °C, and an injection volume of 5 μL was used. Turbo ion 
spray was operated employing the following parameters: gas 1 and 2: 50 psi and curtain gas: 10 psi. The ion spray 
voltage was set to −4500 V, the declustering potential to −40.0 V, the entrance potential to −10.0 V, the collision 
exit potential to −5 V, and the collision energy to −24 V. Detection was performed in multiple reaction moni-
toring (MRM) mode using the following ion transitions: m/z 147.07 (M - H)− to m/z 84.80 for 2-HG and m/z 
150.07 to m/z 87.80 for the deuterated internal standard. Quantification was achieved using a calibration curve 
constructed from the area ratio of 2-HG to the stable isotope-labelled standard.
3Scientific RepoRts |          (2019) 9:7436  | https://doi.org/10.1038/s41598-019-43891-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
Enantioselective 2-HG analysis. For enantioselective analysis of 2-HG, samples were derivatized accord-
ing to Gibson et al.23. See also supplement.
Data analysis. The HPLC-MS/MS software used was Analyst 1.6.2 (AB Sciex). Further data analysis was 
performed using MS Excel and R (version 3.0.0). For determination of Km Origin Pro (v8.0724, OriginLab 
Corporation, Northampton, MA, USA) was used.
Protein quantification. Protein content of cellular lysates used in the dehydrogenase assay and for Western 
blotting was determined by means of the FluoroProfile® Protein Quantification Kit (Sigma Aldrich). Protein pel-
lets obtained after methanol precipitation were resuspended in 20 mM of sodium dihydrogen phosphate buffer 
with 1.2% SDS. The samples were diluted when necessary in water.
Western blot. Cells were lysed in 20 mM sodium dihydrogen phosphate buffer with 1.2% SDS and adjusted 
to equal protein amounts. Western blots were performed according to standard protocol. Briefly, we used BoltTM 
Bis-Tris Plus gels (4–12%, Invitrogen/ThermoFisher Scientific, Waltham, MA, USA) for SDS-PAGE. Gels were 
blotted onto a 0.45 µM PVDF membrane (Immobilon-P, Merck Millipore, Burlington, MA, USA). Membranes 
were blocked in Roti-Block (Carl Roth, Karlsruhe, Germany) prior to incubation with first antibody (anti-hD2H-
GDH, Catalogue No. 13895-1-AP, Proteintech Group Inc., Rosemont, IL, USA; 1:500, diluted in Roti-Block) 
over night. As secondary antibody, HRP-linked IgG (Amersham NA9340V/GE Healthcare, Little Chalfont, UK) 
was used, diluted in TBS-T (10 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20, pH 7.4) 1:4500. SuperSignal West 
Dura (ThermoFisher Scientific) was added 5 min before imaging, followed by image capture using the BioRad 
VersaDoc imaging system (4000 MP, BioRad Laboratories, Hercules, CA, USA). Coomassie staining was per-
formed for loading control. Relative quantification was performed with ImageLab (version 5.1, BioRad).
qPCR. Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany). The 
Bioanalyzer (Agilent) was used for quality control before cDNA was prepared from 1 µg RNA using SuperScript™ 
II Reverse Transcriptase (Life Technologies, Darmstadt, Germany). Relative D2HGDH messenger RNA (mRNA) 
levels were determined by quantitative polymerase chain reaction (qPCR) using a gene-specific TaqMan assay 
(Hs_00292260) on an ABI Prism 7000 (Applied Biosystems/ThermoFisher Scientific, Waltham, MA, USA). 
Results were analysed with the Sequence Detector Software (Applied Biosystems) using the delta-delta-CT 
method.
Results
HPLC-MS/MS analysis of 2-HG. The D2HDH activity assay is based on the HPLC-MS/MS analysis of 
2-HG on an achiral column; hence, 2-HG enantiomers are not separated. A representative chromatogram of a 
standard sample and an extract of a supernatant from HCT116 IDH2-R172K cells is shown is Fig. 1. 2-HG and its 
deuterated isotopologue elute as symmetrical peaks. For absolute quantification, calibration curves were gener-
ated. Figures of merit established with standard solutions in water are presented in Supplementary Tables S1 and 
S2. The linear range was determined according to the FDA Guide for Bioanalytical Method Validation24. Herein, 
the lower (LLOQ) and the upper limit of quantification (ULOQ) are defined as the lowest, respectively, highest 
point of the calibration curve with an accuracy between 80% and 120%. With an injection volume of 5 µL, the 
LOD of 0.05 µM corresponds to 2.5 fmol. Accuracy and precision were calculated from three spike levels (close 
to LLOQ, medium concentration and close to ULOQ) applied to blank medium and were within the acceptable 
range of 100% ± 15% (±20% at the LLOQ and ULOQ). Recovery was calculated from media with and without 
10% FCS as a protein source and ranged from 101.8% to 125.5%.
Enzymatic activity assay for D-2-HG degradation. Assays published to date measure D-2-HG deg-
radation either photometrically via the reduction of DCIP (dichlorophenol indophenol) or via the production 
of labelled L-glutamate from labelled D-2-HG12,25. The latter assay, however, may be biased by a lower rate of 
Figure 1. Representative chromatograms of 2-HG and the internal standard 2-HG-d3. (a) Standard sample 
(conc[iS] = 10 µM, conc[2-HG] = 14.1 µM), and (b) biological sample (cell culture supernatant of HCT116 
IDH2R172K, conc[iS] = 20 µM, conc[2-HG] = 14.1 µM). iS = internal standard.
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the second step, namely the conversion of αKG to L-glutamate. For our assay, enantiomerical pure D-2-HG was 
added to cell homogenates and the decline in 2-HG concentration was analysed quantitatively by HPLC-MS/
MS. Enantioselective test measurements of cell extract and assay aliquots showed, that only the D-form of 2-HG 
was present in the samples and, therefore, we measured indeed only the degradation of D-2-HG (Supplementary 
Figs S1 and S2).
HEPES buffer (20 mM) was used for cell lysis by sonication as described25. Cells used for measuring D2HDH 
activity have to be used directly without freezing to avoid loss of enzyme activity (see Fig. 2a). Since D2HDH 
oxidizes D-2-HG to αKG, an oxidizing agent must be added to the reaction mix. Different agents have been used 
as redox equivalents in published assays such as the endogenously utilized flavin adenine dinucleotide (FAD)12, 
iodonitrotetrazolium (INT)26, and phenazine methosulfate (PMS)25. Therefore, FAD, INT, and PMS were tested 
and compared to each other using substrate concentrations that yielded a slope of linear degradation. At a sub-
strate concentration of 20 µM D-2-HG, FAD gave the lowest, and PMS the highest D2HDH enzyme activity 
(see Fig. 2b, ANOVA: p = 2.04 × 10−15, TukeyHSD PMS vs INT: p = 3.80 × 10−14, PMS vs FAD: p = 3.60 × 10−14, 
FAD vs INT: p = 1.70 × 10−4). Therefore, PMS was used as redox equivalent. Furthermore, the impact of pH 
on D-2-HG degradation was tested by performing the assay at three different pH-values: 7.0, 7.6, and 8.0. 
Again, by comparing the slopes, D-2-HG degradation was found to be highest at pH 7.6 (see Fig. 2c; ANOVA: 
p = 3.01 × 10−4; TukeyHSD pH 7.6 vs pH 8: p = 9.18 × 10−3, pH 7.0 vs pH 7.6: p = 1.74 × 10−4, pH 7.0 vs pH 8.0: 
p = 1.66 × 10−3). This corresponds to the pH milieu found in the mitochondrion27.
Figure 2. The D2HDH assay was optimized by testing different assay conditions using cell homogenates 
from MCF7 cells. In all plots, 2-HG concentration normalized to protein content per aliquot was set 100% at 
t = 0 min. (a) Frozen cell pellets yield lower enzymatic rates than freshly prepared cell pellets (n = 5 for both). 
(b) Impact of different redox equivalents: PMS shows a significantly higher degradation rate than FAD and INT 
(ANOVA: p = 2.04 × 10−15). (c) pH 7.0, pH 7.6, and pH 8.0 were compared to establish optimal pH conditions 
for the D2HDH activity assay. D-2-HG degradation rate was highest at pH 7.6 (ANOVA: p = 3.01 × 10−4), 
reflecting mitochondrial pH.
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D2HDH activity in different cell lines. Using the final assay protocol, the Km value for D-2-HG in MCF7 
cells, a human breast cancer cell line, was determined by applying different D-2-HG concentrations to aliquots 
of the same cellular lysate. By means of this approach the Km of D2HDH in MCF7 cells was approximated to be 
26.4 µM (standard error 1.65, R2adj = 0.99718; n = 3 per data point, two independent experiments; see Fig. 3a) 
using the hill function (n = 1 for a single substrate model) in OriginPro 8. Applying the assay to the acute lymph-
oblastic leukaemia T-cell line C7H2 and the fibrosarcoma cell line HT1080, respectively, showed C7H2 cells to 
have a D2HDH activity similar to that of MCF7 cells, while HT1080 cells showed a lower activity with a vmax 
of about 3 nmol/(mg total protein × h) (see Fig. 3b). This is especially intriguing, as HT1080 cells carry an 
IDH1-R132C mutation and, therefore, produce high endogenous intracellular levels of D-2-HG that are more 
than >500-fold higher than those of MCF7 or C7H2 cells (see Supplementary Table S3). To exclude the pertur-
bation of D-2-HG degradation measurements by D-2-HG production within the lysate, stable-isotope labelled 
αKG was added instead of D-2-HG. Formation of the corresponding labelled D-2-HG by mutated IDH was not 
observed (see Supplementary Fig. S3).
It should be noted that enzymatic rates are normalized to total protein amount in the cell lysate. However, 
in addition to enzyme kinetics, regulation of enzyme activity may occur by changes in D2HDH protein expres-
sion. Furthermore, posttranslational enzyme modifications resulting in altered enzyme characteristics may 
contribute to differences in degradation rates. Therefore, we analysed D2HDH protein expression by Western 
blot. The observed differences in maximal degradation capacity were not reflected in D2HDH protein abun-
dance in HT1080 cells (see Fig. 3c). Contrary to the lower degradation capacity, D2HDH protein abundance in 
HT1080 cells was about 1.45-fold higher compared to that of MCF7 cells (see Supplementary Table S4). Generally, 
D2HDH protein abundance did not vary much across the cell lines tested, though expression differences were 
significant for some cell lines (see Supplementary Table S4).
As stated earlier, we expected HT1080 cells to have increased D2HDH activity as a consequence of IDH1 
mutation and high endogenous D-2-HG levels. Apparently, D2HDH expressed in HT1080 cells does not fulfil the 
expectation of a positive feedback to increase D-2-HG degradation. To the best of our knowledge, these cells do 
not express mutated D2HDH. Protein abundance was slightly elevated, while isoelectric focusing yielded incon-
clusive results. Still, we were asking whether D2HDH is regulated in response to D-2-HG levels. Therefore, MCF7 
Figure 3. Enzyme activity and protein abundance of D2HDH was tested in three different cell lines. (a) Using 
MCF7 cells, a Km of 26.4 µM (standard error 1.65; n = 3) was determined for D2HDH. (b) Comparison of 
three different cell lines shows D2HDH activity to be lower in HT1080 than MCF7 and C7H2 cells. (c) Relative 
protein abundance for D2HDH (normalized to MCF7) is different for the cell lines tested but does not reflect 
D2HDH enzyme activity. (n = 3, ANOVA p: 0.0007, TukeyHSD: HT1080 vs. C7H2 p = 8.20 × 10−6; MCF7 
vs. C7H2 p = 9.23 × 10−4, MCF7 vs. HT1080 p = 2.51 × 10−4). For Western blot data see also Supplementary 
Fig. S4.
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cells characterized by endogenously low D-2-HG levels (0.042 nmol/mg protein ± 18.3%) were treated with 1 mM 
and 5 mM D-2-HG for 24 h and 48 h. The treatment increased neither enzyme activity nor D2HDH abundance 
(see Fig. 4). In addition, the impact of 1 mM D-2-HG treatment on MCF7 and C7H2 cells was checked at the 
D2HGDH mRNA-level but was not found to be upregulated (see Supplementary Fig. S5).
Measuring intracellular 2-HG level in MCF7 cells after treatment showed that uptake of D-2-HG resulted in 
2-HG levels that were about two orders of magnitude lower compared to the concentration of 85 nmol 2-HG/
mg protein in HT1080 cells. Consequently, these experiments were repeated with the HCT116 cell panel con-
taining a parental cell line and three cell lines with different IDH mutations (IDH1-R132H/+, IDH2-R172K/+, 
and IDH2-R140Q/+). The latter cells carrying IDH1/2-mutations produce D-2-HG endogenously, which was 
confirmed by quantifying intracellular (as well as extracellular) concentrations (see Supplementary Table S3). The 
parental HCT116 line showed baseline levels that were comparable to those of MCF7 cells. Cells with a mutation 
had clearly elevated levels. This was particularly true for cells carrying IDH1-R132H and IDH2-R172K muta-
tions: their 2-HG levels were comparable to those of HT1080 cells. The 2-HG levels of the IDH2-R140Q clone 
was higher than that of parental HCT116 but lower than that of the IDH2-R172K clone, which is in agreement 
to published data28. Protein expression, on the other hand, was higher in the parental and IDH mutant HCT116 
clones relative to the MCF7 cell line (see Fig. 5 and Supplementary Table S4). There is a tendency of higher 
D2HDH expression in the IDH mutant HCT116 clones compared to the parental clone, but the difference is only 
significant for IDH2-R140Q (ANOVA p = 0.0275, TukeyHSD par vs R140Q: p = 0.0324, see Fig. 5). Differences 
in D-2-HG degradation were difficult to detect; most likely, differences in activity were smaller than the assay 
variance (see Supplementary Fig. S6). When comparing degradation at a concentration reflecting vmax of MCF7 
Figure 4. Enzyme activity of D2HDH in MCF7 does not change as a function of D-2-HG concentration and 
duration of treatment: (a) 24 h (ANOVA p = 0.7789) or (b) 48 h (ANOVA p = 0.0694) (n = 2 for each time 
point). D2HDH protein abundance in MCF7 after 24 h (c) and 48 h (d) of D-2-HG treatment, (n = 3) from 
Western blot. No significant difference in protein abundance was observed, ANOVA: p = 0.50478 (c) and 
p = 0.06892 (d), respectively.
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of around 50 pmol 2-HG/µg protein, it can be seen that slopes of degradation of HCT116 cells differ (Fig. 5a). 
These differences could be due to the observed differences in D2HDH protein levels (Fig. 5c and Supplementary 
Table S4). We recalculated the slopes using the fold changes in D2HDH protein abundance to correct for differ-
ential expression (Fig. 5b). Using these data, the degradation rate for MCF7 cells was clearly higher at the chosen 
concentration, while degradation rates among the HCT116 clones differed only slightly.
Comparing production of D-2-HG by mutIDH versus its degradation by D2HDH. Pusch et al.21 
had determined for IDH1-R132H (expressed and purified from E. coli) a Km of 243.7 µM using αKG as a sub-
strate. To compare in vitro D-2-HG production by mutated IDH1/2 and D-2-HG degradation by D2HDH, we 
performed both assays with pellets harvested from the same cell passage using an excess of the correspond-
ing substrate and the endogenous redox equivalents. The D2HDH assay was performed in the presence 2 mM 
FAD. For the determination of IDH activity, we adapted the assay from Pusch et al.21 using a Tris-HCl buffer 
for cell lysis by sonication and quantifying 2-HG production over time after the addition of 1 mM to 10 mM 
α-ketoglutarate and 10 mM NADPH. Rate of D-2-HG production determined with this assay matched quite well 
intra- and extracellular 2-HG concentrations for the HCT116 panel (see Supplementary Table S3). 2-HG pro-
duction in the parental cell line was found to be lowest, while HCT116 IDH1-R132H showed the highest 2-HG 
production rate as well as cellular levels (see Fig. 6c).
Compared to IDH, which is a low affinity/high capacity enzyme, D2HDH is a high affinity/low capacity 
enzyme. Therefore, D-2-HG degradation can already be measured at low D-2-HG concentrations, whereas 
for D-2-HG production high amounts of αKG have to be added to detect D-2-HG formation. On the other 
hand, maximum enzyme activity is reached at lower substrate concentrations of ~200 µM D-2-HG for D2HDH. 
However, when incubating cell homogenates without adding exogenous redox equivalents, D-2-HG concentra-
tion does not change significantly. Hence, we conclude that D-2-HG production and degradation do not impact 
each other when performing the respective assay. Running both assays at ~vmax clearly demonstrated that D-2-HG 
production exceeded D-2-HG degradation (see Fig. 6a,b, Table 1), resulting in an accumulation of D-2-HG as 
observed in vivo.
Figure 5. Comparing degradation rates for D-2-HG. (a) Degradation rates of D-2-HG by D2HDH in MCF7 
and different HCT116 cells are shown at vmax of MCF7 (n = 2–3). (b) Degradation rates were recalculated 
correcting for differences in D2HDH protein abundance. (c) D2HDH abundance by Western blot in cells of the 
HCT116 panel and in MCF7 cells were normalized to expression in parental HCT116. Expression differences 
are significant between parental HCT116 and IDH2-R140Q (TukeyHSD p = 0.0324) and for MCF7 against all 
HCT116 panel cell lines (n = 3–7, see Supplementary Table S4).
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Discussion
Elevated D-2-HG levels impact prognosis and therapy of patients with mutated IDH1/2 tumours like glioma 
or AML. They are also problematical for HG-aciduria patients. 2-HG is involved in the development and pro-
gression of these diseases and antibodies targeting mutated IDH1/2 in cancer can prolong survival in treated 
patients29,30. However, only for 2-HG-aciduria patients the mechanism of impaired 2-HG elimination is known. 
For IDH1/2 mutant tumours, it has been only speculated that D-2-HG production is higher than D-2-HG deg-
radation19. However, this assumption is based on kcat of D2HDH in Arabidopsis thaliana, which was compared to 
human mutated IDH. In addition to Km = 243.7 µM for IDH1-R132H from Pusch et al.21, Dang et al.5 determined 
the Km of hIDH1-R132H expressed and purified from E. coli to be at 965 µM (for αKG as substrate). Conversely, 
both groups were not able to identify D-2-HG production by wild type IDH1. Though these two Km-values 
Figure 6. Comparison of D-2-HG formation by mutated IDH to D-2-HG degradation by D2HDH in cell-based 
enzyme assays in (a) HCT116 IDH1-R132H cells and (b) HCT116 IDH2-R172K cells (n = 2): Degradation 
capacity is found low and is not further increased at higher substrate concentrations. In this assay degradation 
is already at vmax with D-2-HG spike added on endogenous D-2-HG resulting in c(2-HG) > 200 µM. In contrast, 
formation of D-2-HG still increases upon increasing the concentration of α-ketoglutarate from 1 mM to 10 mM, 
proving a high D-2-HG production capacity. Again, endogenous D-2-HG raises the starting level in the 2-HG 
production assay. (c) Reaction velocity as a function of αKG-concentrations normalized to total protein for the 
HCT116 cell panel (wild type IDH and different IDH1/2 mutations).
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for IDH1-R132H do not completely agree, they show the same effect of an increased D-2-HG production by 
IDH1-R132H compared to wild type IDH15. Nevertheless, it was not known how functional human D2HDH can 
deal with elevated D-2-HG levels. We could show that treatment of MCF7 cells with D-2-HG increased neither 
D2HGDH mRNA and D2HDH protein abundance nor D-2-HG degradation in comparison to untreated cells. 
Similarly, in HCT116 cells with endogenous D-2-HG, produced from mutated IDH1/2, degradation capacity 
was not drastically increased, though our data show high variation here. In addition, D2HDH protein was only 
significantly upregulated in HCT116 IDH2-R140Q in comparison to parental HCT116 with a 1.19-fold increase 
in relative abundance.
Here, we compared directly production and degradation of D-2-HG by mutated IDH1/2 and D2HDH, respec-
tively. Regarding D-2-HG degradation, the Km of 26.4 µM determined by our assay in the human breast ade-
nocarcinoma cell MCF7 clearly exceeded the Km values of 4.3 µM and 3.2 µM reported previously for human 
fibroblasts25 and rat liver12. Nevertheless, Km values for D2HDH in mammalian cells are obviously much lower 
than the Km value of ~580 µM reported for D2HDH from Arabidopsis thaliana31. Low Km values indicate a 
high affinity of the enzyme to its substrate, which is typical for low concentrated substrates such as D-2-HG in 
healthy humans. This is also in line with the general suggestion of D2HDH being a metabolic repair enzyme18,32. 
Expression of D2HDH protein varied slightly between the cell lines tested here. Nevertheless, expression differ-
ences did not correlate with D-2-HG levels. For instance, Han et al. found that D2HGDH expression is upregu-
lated upon HIF1α-stabilization33. However, it was also reported that HIF1α/-2α levels varied depending on the 
cell passage number34. In addition, it has been supposed that D-2-HG destabilizes HIF134,35. Therefore, current 
knowledge is quite controversial with a lot of players impacting on each other. Perhaps this also contributed to the 
high variation in our D2HDH-assay data for the HCT116 panel. Further, from Table 1 it is obvious that the rates 
of production of D-2-HG by mutated IDH1/2 clearly exceeded those of its degradation by D2HDH when meas-
ured at maximum enzyme saturation (vmax) and accounting for differences in protein expression of the enzymes.
For D-2-HG degradation, enzyme saturation might reflect physiological conditions with D2HDH being a 
high affinity/low capacity enzyme. However, for mutated IDH1/2 it is hard to evaluate how closely in vitro con-
ditions mimic intracellular conditions. For mutated IDH1, it is known that D-2-HG production is limited by 
substrate availability28 and relies on intact wild type IDH1 activity, which can sufficiently refuel αKG. With regard 
to the close spatial proximity, one might speculate that local αKG concentrations are high enough for D-2-HG 
production at vmax. For mutated IDH2, substrate availability is not an issue. It is speculated that there is effective 
regeneration of αKG by a network of enzymes, which tightly regulate mitochondrial αKG-levels via anaplerosis. 
For instance, there is conversion of glutamate to αKG in mitochondria (GLUD1/2, GOT2) and even in the cytosol 
(GOT1).
However, in vivo further events like substrate inhibition and export might affect net D-2-HG degradation 
and support negative D-2-HG mediated effects. Accordingly, Gelman et al. could not find many intracellular 
metabolic products originating from 2-HG degradation when attempting to track the fate of U-13C-2-HG admin-
istered to the HCT116 cell panel36. Moreover, with regard to the effect of D-2-HG on immune cells and, conse-
quently, on immune response35,37,38, D2HDH activity of different types of immune cells might be worth studying.
In conclusion, our observations confirm that D-2-HG degradation is rather slow in comparison to its produc-
tion in cells harbouring mutant IDH. This explains especially the high accumulation of D-2-HG in glioma tissue5, 
where there is no export into and distribution across other body fluids. Furthermore, our experiments show that 
D2HDH activity is different across the cell lines tested here. There are hints that expression of D2HDH is upreg-
ulated in the presence of high endogenous concentrations of D-2-HG.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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